To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Talking about MMN
Understand the real-world burden of MMN from the patient perspective
Assessing the disease burden
The burden of MMN
Based on the findings of the first global MMN QoL survey (N=211), MMN restricts daily activities and impacts emotional well-being and overall QoL:1,a
of respondents reported an impact on overall QoL
62% reported impacts on activities of daily living and household chores
75% reported exhaustion, 75% reported fatigue and 78% reported daytime drowsiness
27% reported difficulty walking and 42% reported difficulty climbing stairs
46% reported impacts on emotional well-being, including symptoms of depression, and 28% reported feelings of hopelessness
53% reported muscle weakness and 20% reported cramping
46% reported impacts on work activities
55% reported impacts on social life and activities
- Muscle weakness is often significant, predominantly impacting upper or lower extremities, and may lead to progressive loss of function, an inability to perform daily tasks, decreased work productivity, and irreversible disability over time2–4
- Disabilities associated with MMN can severely affect QoL, including psychological and economic impacts, regardless of whether they are obvious or ‘invisible’5
- MMN interferes with employment, and half of individuals report difficulties concentrating and typing on a computer or using a telephone1
The patient perspective
Watch Richard Sperry, a patient living with MMN, discuss his experience of the disease with Lisa Butler, CEO of the GBS/CIDP Foundation:
Richard’s perspective on living with MMN
“Things like writing, shaving, typing, picking up a cup of coffee just became almost impossible”
Richard’s perspective on his journey to an MMN diagnosis
“I’ve counted the number of neurologists [I’ve seen up to my MMN diagnosis], and I would probably say close to two dozen, close to 25”
Richard’s perspective on his expectations for MMN
“I would want neurologists…to really think about the whole individual…and think about them holistically, not just the medication and treatment”
Hear from other patients living with MMN
Watch British Army veteran and patient living with MMN Clive Phillips introducing the ‘Tour de MMN’ 2025
Watch Brenda’s MMN story
Resources
Footnotes:
aCompleted by 211 individuals with MMN in 2016: 53% women, 89% white, >70% located in the United States.1
Abbreviations:
CIDP=chronic inflammatory demyelinating polyradiculoneuropathy; GBS=Guillain-Barré syndrome; MMN=multifocal motor neuropathy; QoL=quality of life.
References:
1. Katz J, et al. First global multifocal motor neuropathy (MMN) quality of life (QOL) patient survey identifies needs in education and treatment. May 23, 2024. Available at: www.neuropathyaction.org/downloads/MMN_article%209-26-2016.pdf. (Accessed: October 2025); 2. van Schaik IN, et al. Eur J Neurol. 2006;13(8):802–808. doi:10.1111/j.1468-1331.2006.01466.x; 3. Gable KL, et al. Burden of disease in multifocal motor neuropathy: A global quantitative survey of patients. Poster presented at the 2025 Peripheral Nerve Society (PNS) Annual Meeting; May 17–20, 2025; Edinburgh, UK; 4. Vlam L, et al. Nat Rev Neurol. 2011;8(1):48–58. doi:10.1038/nrneurol.2011.175; 5. Allen JA, et al. Mayo Clin Proc Innov Qual Outcomes. 2024;8(1):74–81. doi:10.1016/j.mayocpiqo.2023.12.002.
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2026 argenx MED-US-NON-2400036 v6 04/2026. All Rights Reserved.